



Laszlo Radvanyi earned his Ph.D. degree in Clinical Biochemistry in 1996 at the University of Toronto, Toronto, Canada. He is currently Chief Scientific Officer of Lion Biotechnologies (as of June 2014) developing T-cell therapies for solid tumors, with an established R&D facility at the University of South Florida Innovation Complex (USF Connect) in Tampa, FL. He is also an Adjunct Member Faculty in the Immunology Department at H. Lee Moffitt Cancer Center where he shares a lab and does basic research on NIH-funded projects on tumor immunology. Previously, Dr. Radvanyi was a Professor in the Department of Melanoma Medical Oncology at the University of Texas, M.D. Anderson Cancer Center in Houston from 2005 to 2014. While at M.D. Anderson, he established a GMP-grade T-cell therapy manufacturing program for metastatic melanoma using expanded tumor-infiltrating lymphocytes (TIL) and did pre-clinical research mentoring numerous graduate students and postdoctoral fellows. His current work at Lion Biotechnologies focuses on developing current and next generation cell therapies for melanoma and other solid cancers using expanded TIL. He also performs basic and translational research identifying biomarkers in T-cell therapy, improving the anti-tumor function of expanded T cells, and developing improved manufacturing methods for T-cell therapy in collaboration with researchers at Moffitt Cancer Center and other centers. His team is also interested in developing alternative forms of Interleukin-2 for clinical use in T-cell therapy that are less toxic and do not activate T-regulatory cells. Dr. Radvanyi has authored over 90 manuscripts, has served on the advisory board of a number of pharma companies, reviewed for numerous journals in the tumor immunology and immunotherapy space, and sits on a number of national and international grant review panels.